1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Evopoint Biosciences Co. Ltd.

Evopoint Biosciences Co. Ltd.

688837.SS
Evopoint Biosciences Co. Ltd.CN flagShanghai Stock Exchange
49.40
CNY
+5.79
- -
24.74BMarket Cap
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.06
- -
- -
2.54
Basic EPS, GAAP
-1.42
-1.25
-1.05
0.55
Free Cash Flow per Basic Share
-1.78
-1.35
-1.09
0.31
Dividend per Share
0.02
0.04
0.04
0.07
Book Value per Share
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
Basic Weighted Avg Shares
326
342
368
368
Sales/Revenue/Turnover
20
- -
- -
935
Operating Margin (%)
-2,645.69
- -
- -
22.75
Depreciation Expense
15
18
26
40
Net Income, GAAP
-463
-427
-386
203
Effective Tax Rate (%)
- -
- -
- -
31.4
Profit Margin (%)
-2,372.47
- -
- -
21.66
Working Capital
276
361
116
603
LT Debt
286
345
398
728
Total Equity
459
579
359
703
Return on Invested Capital (%)
- -
- -
- -
11.74
Return on Capital (%)
- -
- -
- -
17.64
Return on Common Equity (%)
- -
-82.22
-82.26
38.13

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
95.58%
Free Cash Flow
- -
- -
-128.95%
Net Income, GAAP
- -
- -
-152.48%
Sales/Revenue/Turnover
- -
- -
4,696.12%
Total Cash Common Dividend
- -
- -
47.39%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
935
2026
4
172
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-1.05
2025
- -
- -
- -
- -
0.55
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.07
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mei Jie Le
Full Time Employees
362
Sector
Healthcare
Industry
Biotechnology
Address
Building 22, Area B, 218 Sangtian Street, Suzhou Industrial Park Suzhou JS People's Republic of China 215000
IPO Date
Sep 16, 2026
Website
evopointbio.com
Similar Companies
Mindset Pharma Inc. (MSSTF)
Amplia Therapeutics Limited (INNMF)
Mirxes Holding Company Limited (2629.HK)
Intensity Therapeutics, Inc. (INTS)
Simris Alg AB (publ) (SIMRIS-B.ST)
Lyka Labs Limited (LYKALABS.BO)
Business
Evopoint Biosciences Co., Ltd. operates as a biopharmaceutical company that offers therapies for patients with oncology and multidrug-resistant infections. The company's three core technology platforms are a Small Molecule Drug Discovery Platform, a Novel Antibody Discovery Platform, and a Targeted Protein Degradation Platform. Several of its pipeline products have advanced to Phase III clinical trials or the New Drug Application stage.